Aura Biosciences raises $86.7M in public offering of 7.7M shares at $12.00/share

Aura Biosciences, Inc.

Net proceeds of ~$86.7M from 7.705M shares (including full overallotment) at $12.00 per share.
Proceeds to advance belzupacap sarotalocan for choroidal melanoma and NMIBC, plus platform and corporate.
Management expects cash runway to fund operations into 2025.
Offering closed Dec 5, 2022; underwriters led by SVB Securities, Cowen, Evercore.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aura Biosciences, Inc. entered into Underwriting Agreement with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C valued at 6,700,000 shares of common stock at $12.00 per share, with option for additional 1,005,000 shares (effective 2022-11-30).

Action: entry
Agreement: underwriting
Counterparty: SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C
Value: 6,700,000 shares of common stock at $12.00 per share, with option for additional 1,005,000 shares
Effective: 2022-11-30

Exact text from the filing

On November 30, 2022, Aura Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with SVB Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C, as representatives of the several underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 6,700,000 shares of the Company’s common stock, par value $0.00001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $12.00 per share (the “ Offering ”).

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-298535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.